Lonza Group AG LZAGY Stock
Lonza Group AG Price Chart
Lonza Group AG LZAGY Financial and Trading Overview
Lonza Group AG stock price | 57.21 USD |
Previous Close | 63.1 USD |
Open | 62.11 USD |
Bid | 0 USD x 0 |
Ask | 0 USD x 0 |
Day's Range | 62.11 - 63.47 USD |
52 Week Range | 43.85 - 66 USD |
Volume | 137.03K USD |
Avg. Volume | 56.84K USD |
Market Cap | 47.11B USD |
Beta (5Y Monthly) | 0.622222 |
PE Ratio (TTM) | 35.233334 |
EPS (TTM) | 1.04 USD |
Forward Dividend & Yield | 0.39 (0.61%) |
Ex-Dividend Date | May 9, 2023 |
1y Target Est | N/A |
LZAGY Valuation Measures
Enterprise Value | 47.3B USD |
Trailing P/E | 35.233334 |
Forward P/E | 2.9401946 |
PEG Ratio (5 yr expected) | 0.15 |
Price/Sales (ttm) | 7.5702057 |
Price/Book (mrq) | 4.4455347 |
Enterprise Value/Revenue | 7.601 |
Enterprise Value/EBITDA | 24.922 |
Trading Information
Lonza Group AG Stock Price History
Beta (5Y Monthly) | 0.622222 |
52-Week Change | 24.47% |
S&P500 52-Week Change | 20.43% |
52 Week High | 66 USD |
52 Week Low | 43.85 USD |
50-Day Moving Average | 63.66 USD |
200-Day Moving Average | 55.91 USD |
LZAGY Share Statistics
Avg. Volume (3 month) | 56.84K USD |
Avg. Daily Volume (10-Days) | 117.79K USD |
Shares Outstanding | 742.82M |
Float | 742.13M |
Short Ratio | N/A |
% Held by Insiders | 0% |
% Held by Institutions | 0.14% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 3.5 |
Trailing Annual Dividend Yield | 5.54% |
5 Year Average Dividend Yield | 57.99% |
Payout Ratio | 0.1768 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | December 31, 2022 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | 19.52% |
Operating Margin (ttm) | 22.28% |
Gross Margin | 39.17% |
EBITDA Margin | 30.50% |
Management Effectiveness
Return on Assets (ttm) | 5.12% |
Return on Equity (ttm) | 11.89% |
Income Statement
Revenue (ttm) | 6.22B USD |
Revenue Per Share (ttm) | 8.38 USD |
Quarterly Revenue Growth (yoy) | 13.00% |
Gross Profit (ttm) | 2.44B USD |
EBITDA | 1.9B USD |
Net Income Avi to Common (ttm) | 1.22B USD |
Diluted EPS (ttm) | 1.8 |
Quarterly Earnings Growth (yoy) | -72.50% |
Balance Sheet
Total Cash (mrq) | 2.22B USD |
Total Cash Per Share (mrq) | 2.99 USD |
Total Debt (mrq) | 2.59B USD |
Total Debt/Equity (mrq) | 24.26 USD |
Current Ratio (mrq) | 1.856 |
Book Value Per Share (mrq) | 14.266 |
Cash Flow Statement
Operating Cash Flow (ttm) | 1.02B USD |
Levered Free Cash Flow (ttm) | -988249984 USD |
Profile of Lonza Group AG
Country | United States |
State | N/A |
City | Basel |
Address | Muenchensteinerstrasse 38 |
ZIP | 4002 |
Phone | 41 61 316 81 11 |
Website | https://www.lonza.com |
Industry | Diagnostics & Research |
Sector(s) | Healthcare |
Full Time Employees | 17494 |
Lonza Group AG, together with its subsidiaries, supplies various products and services for pharmaceutical, biotech, and nutrition markets in Europe and internationally. It operates through Biologics, Small Molecules, Cell & Gene, and Capsules & Health Ingredients segments. The Biologics segment engages in the contract development and manufacturing of biopharmaceuticals for clinical and commercial manufacturing needs throughout the product lifecycle, including drug substance and drug product manufacturing. The Small Molecules segment operates as an integrated development and manufacturing service provider for small molecule drug substances and their intermediates. It supports customers across various aspects of design, development, and manufacturing. The Cell & Gene segment develops technologies and platforms that industrialize the manufacturing processes and production of cell and gene therapies. It also offers contract development and manufacturing services, and regulatory support for a range of allogeneic and autologous cell therapies, and exosome-based therapies, as well as viral vector gene therapies. In addition, this segment provides Cocoon platform, a closed automated system for patient-scale cell therapy manufacturing; and specialty raw materials and enabling technology solutions in cell and gene therapy, injectable drugs, vaccines, and bio-manufacturing markets. The Capsules & Health Ingredients segment offers capsules, dosage form solutions, and health ingredients for pharmaceutical and nutraceutical customers. The company was incorporated in 1897 and is headquartered in Basel, Switzerland.
Q&A For Lonza Group AG Stock
What is a current LZAGY stock price?
Lonza Group AG LZAGY stock price today per share is 57.21 USD.
How to purchase Lonza Group AG stock?
You can buy LZAGY shares on the OTC Markets OTCPK exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Lonza Group AG?
The stock symbol or ticker of Lonza Group AG is LZAGY.
Which industry does the Lonza Group AG company belong to?
The Lonza Group AG industry is Diagnostics & Research.
How many shares does Lonza Group AG have in circulation?
The max supply of Lonza Group AG shares is 721.43M.
What is Lonza Group AG Price to Earnings Ratio (PE Ratio)?
Lonza Group AG PE Ratio is 55.00961700 now.
What was Lonza Group AG earnings per share over the trailing 12 months (TTM)?
Lonza Group AG EPS is 1.04 USD over the trailing 12 months.
Which sector does the Lonza Group AG company belong to?
The Lonza Group AG sector is Healthcare.